Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Revolutionizing Skin Health with our Advanced Engineered Biotherapeutics

Project description

Engineered bacteria: the future of acne care

Traditional skin treatments often suffer from poor penetration, while invasive procedures and antibiotic resistance present significant health challenges. The EIC-funded SkinEngineering project aims to address these issues by using genetically engineered skin bacteria (Cutibacterium acnes) to deliver biotherapeutics directly into hair follicles. These modified microbes continuously secrete therapeutic molecules, providing a safe, long-lasting treatment. Beyond preclinical and regulatory validation, the project will implement robust safety biocontainment strategies. This non-invasive approach will offer a sustainable alternative to antibiotics, addressing the global challenge of antimicrobial resistance while targeting a massive international skincare market. Ultimately, the project will focus on refining a commercial strategy to attract investors and pharmaceutical partners.

Objective

We have developed a ground-breaking patented technology that uses genetically engineered skin bacteria (C. acnes) to deliver biotherapeutics directly to the skin, offering safe, effective and long-lasting treatment for skin conditions such as acne. Our modified microbes continuously produce and secrete therapeutic molecules in the hair follicle, addressing the problems associated with invasive procedures and the poor transdermal penetration of traditional topical treatments.
Preclinical results from our previous EIC Transition project SKINDEV (coordinated by UPF), have demonstrated significant efficacy in reducing sebum and inflammation in vitro. Additionally, further studies have shown successful engraftment and safety in mouse models. The SkinEngineering project will advance our technology from proof-of-concept (TRL3) to preclinical and regulatory validation (TRL5), bridging the gap between promising research outcomes and the stage where we are ready to enter into commercial agreements with potential partners.
SkinEngineering will help us further refine our platform, complete preclinical studies and address regulatory and manufacturing aspects. We will also focus on ensuring the safety of our engineered bacteria, including robust biocontainment strategies. We have preliminarily validated the market fit of this effective and non-invasive therapy without adverse effects, confirming that it meets the needs of clinicians and patients in the €14 billion acne market. Our biotherapeutic also reduces the need for antimicrobial-based treatments, helping combat antimicrobial resistance, a key public health issue.
Our commercialization pathway involves launching a spin-off, Synflora, with SkinEngineering refining our business model and go-to-market strategy. Successful project outcomes will capture the attention of key stakeholders, e.g. investors, pharma/cosmetic companies and end users, boosting our company’s awareness and enhancing its investment readiness.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-TRANSITION-01

See all projects funded under this call

Coordinator

UNIVERSIDAD POMPEU FABRA
Net EU contribution
€ 2 499 999,00
Address
PLACA DE LA MERCE, 10-12
08002 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data